Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.

Authors:

Abstract
2500 Background: Phosphatidylinositol-3-kinase (PI3K) and fibroblast growth factor receptor (FGFR) pathway dysregulation can co-occur in tumors. In this study (NCT01928459), safety, tolerability, and preliminary activity of the pan-FGFR (BGJ398) + α-specific PI3K (BYL719) inhibitors were evaluated and maximum tolerated dose (MTD) was established in pts w/ advanced solid tumors w/ PI3K catalytic subunit (PIK3CA) mutations ± FGFR alterations. Methods: Pts w/ solid tumors received once-daily (QD) BGJ on D1-D21 of each 28-D cycle (C) and BYL continuously during escalation (PIK3CA-mutant ± FGFR-altered) and expansion (arm 1, PIK3CA-mutant [n = 15]; arm 2, PIK3CA-mutant + FGFR-altered [n = 10]; arm 3, PIK3CA-mutant + FGFR-altered breast cancer [n = 10]). Results: Of 62 pts enrolled, 44% had ≥ 4 prior therapies. The MTD, 125 BGJ + 300 BYL, was determined based on 32 evaluable pts’ data during escalation. C1 dose-limiting toxicities (DLTs) occurred in 4 pts (table). During expansion, 24 pts in arms 1 (n = 12), 2 (n = 6), and 3 (n = 6) received the MTD. At data cutoff (Nov 6, 2015), 4 pts were ongoing; median treatment duration was 64 D (range, 7-456 D). Common adverse events (AEs) included diarrhea (60%), fatigue (53%), nausea (48%), and on-target AEs (hyperphosphatemia [37%], hyperglycemia [36%]); most were G1/2. At the MTD, 61% of pts had ≥ 1 BGJ dose reduction; 61% of pts had ≥ 1 BYL dose reduction. Eight pts had partial responses (PRs), w/ 4 confirmed in urothelial, head and neck, melanoma, and anal cancer. One pt w/ FGFR3-TACC3 fusion urothelial carcinoma w/ PR had a complete shrinkage in target lesions lasting 4 mo. Conclusions: The MTD for BGJ + BYL was determined as QD 125 BGJ on D1-D21 of each C + 300 BYL continuously. Given the high number of reductions w/ chronic treatment, lower starting doses may be warranted in future studies. Responses were observed in tumors w/ specific genetic alterations; however, it is not known if BGJ + BYL in combination offers improved efficacy over single agents. Clinical trial information: NCT01928459.